US3361306A
(en)
|
1966-03-31 |
1968-01-02 |
Merck & Co Inc |
Aerosol unit dispensing uniform amounts of a medically active ingredient
|
US3565070A
(en)
|
1969-02-28 |
1971-02-23 |
Riker Laboratories Inc |
Inhalation actuable aerosol dispenser
|
FR2224175B1
(es)
|
1973-04-04 |
1978-04-14 |
Isf Spa |
|
US4069819A
(en)
|
1973-04-13 |
1978-01-24 |
Societa Farmaceutici S.P.A. |
Inhalation device
|
IT1017153B
(it)
|
1974-07-15 |
1977-07-20 |
Isf Spa |
Apparecchio per inalazioni
|
SE438261B
(sv)
|
1981-07-08 |
1985-04-15 |
Draco Ab |
Anvendning i dosinhalator av ett perforerat membran
|
US4805811A
(en)
|
1985-03-29 |
1989-02-21 |
Aktiebolaget Draco |
Dosage device
|
SE448277B
(sv)
|
1985-04-12 |
1987-02-09 |
Draco Ab |
Indikeringsanordning vid en doseringsanordning for lekemedel
|
US5021456A
(en)
|
1988-02-25 |
1991-06-04 |
Merrell Dow Pharmaceuticals Inc. |
Inhibitors of lysyl oxidase
|
US5252608A
(en)
|
1988-02-25 |
1993-10-12 |
Merrell Dow Pharmaceuticals Inc. |
Inhibitors of lysyl oxidase
|
US4943593A
(en)
|
1988-02-25 |
1990-07-24 |
Merrell Dow Pharmaceuticals Inc. |
Inhibitors of lysyl oxidase
|
US5182297A
(en)
|
1988-02-25 |
1993-01-26 |
Merrell Dow Pharmaceuticals Inc. |
Inhibitors of lysyl oxidase
|
US4965288A
(en)
|
1988-02-25 |
1990-10-23 |
Merrell Dow Pharmaceuticals Inc. |
Inhibitors of lysyl oxidase
|
US5059714A
(en)
|
1988-02-25 |
1991-10-22 |
Merrell Dow Pharmaceuticals Inc. |
Inhibitors of lysyl oxidase
|
US5120764A
(en)
|
1988-11-01 |
1992-06-09 |
Merrell Dow Pharmaceuticals Inc. |
Inhibitors of lysyl oxidase
|
IT1228459B
(it)
|
1989-02-23 |
1991-06-19 |
Phidea S R L |
Inalatore con svuotamento regolare e completo della capsula.
|
US4955371A
(en)
|
1989-05-08 |
1990-09-11 |
Transtech Scientific, Inc. |
Disposable inhalation activated, aerosol device for pulmonary medicine
|
US4997854A
(en)
|
1989-08-25 |
1991-03-05 |
Trustees Of Boston University |
Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in-situ using adjacently positioned diamine analogue substrates
|
US20030125519A1
(en)
|
1990-08-27 |
2003-07-03 |
Peter Besmer |
Ligand for the c-kit receptor and methods of use thereof
|
US6319494B1
(en)
|
1990-12-14 |
2001-11-20 |
Cell Genesys, Inc. |
Chimeric chains for receptor-associated signal transduction pathways
|
DE4205148A1
(de)
|
1991-05-25 |
1993-01-21 |
Boehringer Mannheim Gmbh |
Monoklonale antikoerper gegen c-kit
|
EP0592540B1
(en)
|
1991-07-02 |
2000-01-26 |
Inhale, Inc. |
Method and device for delivering aerosolized medicaments
|
IL104570A0
(en)
|
1992-03-18 |
1993-05-13 |
Yeda Res & Dev |
Chimeric genes and cells transformed therewith
|
US5261538A
(en)
|
1992-04-21 |
1993-11-16 |
Glaxo Inc. |
Aerosol testing method
|
US5785049A
(en)
|
1994-09-21 |
1998-07-28 |
Inhale Therapeutic Systems |
Method and apparatus for dispersion of dry powder medicaments
|
US5388572A
(en)
|
1993-10-26 |
1995-02-14 |
Tenax Corporation (A Connecticut Corp.) |
Dry powder medicament inhalator having an inhalation-activated piston to aerosolize dose and deliver same
|
US5522385A
(en)
|
1994-09-27 |
1996-06-04 |
Aradigm Corporation |
Dynamic particle size control for aerosolized drug delivery
|
US5874540A
(en)
|
1994-10-05 |
1999-02-23 |
Immunomedics, Inc. |
CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
|
US5622163A
(en)
|
1994-11-29 |
1997-04-22 |
Iep Group, Inc. |
Counter for fluid dispensers
|
US5544647A
(en)
|
1994-11-29 |
1996-08-13 |
Iep Group, Inc. |
Metered dose inhalator
|
WO1997027873A1
(en)
|
1996-01-30 |
1997-08-07 |
Brigham & Women's Hospital, Inc. |
Antibodies for modulating cd47-mediated neutrophil transmigration
|
CA2226962A1
(en)
|
1998-02-16 |
1999-08-16 |
Marie Sarfati |
Use of binding agents to cd47 and its ligands in the treatment or the prophylaxis of various inflammatory, autoimmune and allergic diseases and in the treatment of graft rejection
|
US6116234A
(en)
|
1999-02-01 |
2000-09-12 |
Iep Pharmaceutical Devices Inc. |
Metered dose inhaler agitator
|
WO2001040307A1
(de)
|
1999-11-30 |
2001-06-07 |
Eberhard-Karls-Universität Tübingen Universitätsklinikum |
Antikörper gegen signal-regulator-proteine
|
PL360027A1
(en)
|
2000-06-30 |
2004-09-06 |
Wyeth |
Substituted-triazolopyrimidines as anticancer agents
|
AU2002315052A1
(en)
|
2001-05-15 |
2002-11-25 |
Emory University |
Polynucleotides and polypeptides relating to the modulation of sirp alpha-cd47
|
FR2828206B1
(fr)
|
2001-08-03 |
2004-09-24 |
Centre Nat Rech Scient |
Utilisation d'inhibiteurs des lysyl oxydases pour la culture cellulaire et le genie tissulaire
|
US8877901B2
(en)
|
2002-12-13 |
2014-11-04 |
Immunomedics, Inc. |
Camptothecin-binding moiety conjugates
|
US8435529B2
(en)
|
2002-06-14 |
2013-05-07 |
Immunomedics, Inc. |
Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
|
EP1483295B1
(en)
|
2002-03-01 |
2008-12-10 |
Immunomedics, Inc. |
Rs7 antibodies
|
EP1604665B1
(en)
|
2003-03-10 |
2011-05-11 |
Eisai R&D Management Co., Ltd. |
C-kit kinase inhibitor
|
US8362017B2
(en)
|
2003-08-29 |
2013-01-29 |
Exelixis, Inc. |
C-kit modulators and methods of use
|
AU2004287722A1
(en)
|
2003-11-11 |
2005-05-19 |
Chugai Seiyaku Kabushiki Kaisha |
Humanized anti-CD47 antibody
|
US8435539B2
(en)
|
2004-02-13 |
2013-05-07 |
Immunomedics, Inc. |
Delivery system for cytotoxic drugs by bispecific antibody pretargeting
|
RS55551B1
(sr)
|
2004-05-13 |
2017-05-31 |
Icos Corp |
Hinazolinoni kao inhibitori humane fosfatidilinozitol 3-kinaze delta
|
DE602005011617D1
(de)
|
2004-05-19 |
2009-01-22 |
Medigene Ltd |
Hochaffiner ny-eso-t-zellen-rezeptor
|
JP2008503473A
(ja)
|
2004-06-17 |
2008-02-07 |
プレキシコン,インコーポレーテッド |
C−kit活性を調節する化合物
|
US7442716B2
(en)
|
2004-12-17 |
2008-10-28 |
Merck Frosst Canada Ltd. |
2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors
|
WO2006063466A1
(en)
|
2004-12-17 |
2006-06-22 |
Merck Frosst Canada Ltd. |
2-(phenyl or heterocyclic)-1h-phenantrho[9,10-d]imidazoles as mpges-1 inhibitors
|
AU2006218454B2
(en)
|
2005-03-03 |
2011-11-17 |
Immunomedics, Inc. |
Humanized L243 antibodies
|
US9707302B2
(en)
|
2013-07-23 |
2017-07-18 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
US20090142345A1
(en)
|
2005-03-15 |
2009-06-04 |
Takeda Pharmaceutical Company Limited |
Prophylactic/therapeutic agent for cancer
|
US20130039861A1
(en)
|
2005-04-06 |
2013-02-14 |
Immunomedics, Inc. |
Dye Conjugated Peptides for Fluorescent Imaging
|
WO2006124692A2
(en)
|
2005-05-18 |
2006-11-23 |
Wyeth |
3-cyanoquinoline inhibitors of tpl2 kinase and methods of making and using the same
|
MX2007014258A
(es)
|
2005-05-18 |
2008-01-22 |
Wyeth Corp |
Inhibidores de 4,6-diamino-[1,7]naftiridin-3-carbonitrilo de la tpl2 cinasa y metodos de fabricacion y uso de los mismos.
|
TW201402124A
(zh)
|
2005-08-19 |
2014-01-16 |
Array Biopharma Inc |
作為類鐸受體(toll-like receptor)調節劑之8-經取代苯并氮雜呯
|
TWI382019B
(zh)
|
2005-08-19 |
2013-01-11 |
Array Biopharma Inc |
作為類鐸受體(toll-like receptor)調節劑之胺基二氮雜呯
|
US8003770B2
(en)
|
2005-09-13 |
2011-08-23 |
Mie University |
T-cell receptor and nucleic acid encoding the receptor
|
KR100788161B1
(ko)
|
2006-01-06 |
2007-12-21 |
(주)아모레퍼시픽 |
벤즈이미다졸 아민 유도체 또는 아미노퀴놀린 유도체를 함유하는 피부 미백용 조성물
|
TW200740776A
(en)
|
2006-02-06 |
2007-11-01 |
Osi Pharm Inc |
N-phenylbenzotriazolyl c-kit inhibitors
|
US7420041B2
(en)
|
2006-02-24 |
2008-09-02 |
Arius Research Inc. |
Cytotoxicity mediation of cells evidencing surface expression of TROP-2
|
TWI395754B
(zh)
|
2006-04-24 |
2013-05-11 |
Amgen Inc |
人類化之c-kit抗體
|
US20090192158A1
(en)
|
2006-05-02 |
2009-07-30 |
Stacia Kargman |
Methods for Treating or Preventing Neoplasias
|
AU2007249709A1
(en)
|
2006-05-15 |
2007-11-22 |
Viral Logic Systems Technology Corp. |
CD47 related compositions and methods for treating immunological diseases and disorders
|
EP2463295A1
(en)
|
2006-05-22 |
2012-06-13 |
The Regents of The University of California |
Compositions and methods for the delivery of oxygen
|
ITMI20061053A1
(it)
|
2006-05-30 |
2007-11-30 |
Manuli Rubber Ind Spa |
Raccordo per tubi flessibili per applicazioni oleodinamiche,industriali e aria condizionata,avente caratteristiche di tenuta migliorate.
|
WO2008005877A2
(en)
|
2006-06-30 |
2008-01-10 |
Board Of Regents, The University Of Texas System |
Inhibitors of c-kit and uses thereof
|
DE102006058450A1
(de)
|
2006-12-12 |
2008-06-19 |
Eberhard-Karls-Universität Tübingen |
Zubereitungen zur Hemmung der Prostaglandin E2 Synthese
|
PT2170888E
(pt)
|
2007-06-29 |
2015-08-21 |
Gilead Sciences Inc |
Purina derivados e sua utilização como moduladores de recetor de tipo toll 7
|
WO2009017833A2
(en)
|
2007-08-02 |
2009-02-05 |
Arresto Biosciences |
Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis
|
EP2573112A1
(en)
|
2007-10-11 |
2013-03-27 |
The Hospital For Sick Children |
Modulation of sirpa - cd47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor
|
TW200930369A
(en)
|
2007-11-15 |
2009-07-16 |
Astrazeneca Ab |
Bis-(sulfonylamino) derivatives in therapy
|
UY31468A1
(es)
|
2007-11-15 |
2009-07-17 |
|
Derivados bis-(sulfonilamino) en terapia 065
|
US20090163586A1
(en)
|
2007-12-20 |
2009-06-25 |
Astrazeneca Ab |
Bis-(Sulfonylamino) Derivatives in Therapy 205
|
WO2009103778A1
(en)
|
2008-02-19 |
2009-08-27 |
Novasaid Ab |
Compounds and methods
|
WO2009117987A2
(de)
|
2008-03-26 |
2009-10-01 |
Universität Tübingen |
Verwendung von boswelliasäuren und synthetischen boswelliasäurederivaten zur hemmung der mikrosomalen prostaglandin e2 synthase und des cathepsin g
|
WO2009130242A1
(en)
|
2008-04-23 |
2009-10-29 |
Novasaid Ab |
Low molecular weight derivatives and use thereof in treatment of prostaglandin e synthase related diseases
|
EP2119705A1
(en)
|
2008-05-14 |
2009-11-18 |
AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. |
3-Aminocarbozole compound, pharmaceutical composition containing it and preparation method therefor
|
DE102008027331A1
(de)
|
2008-06-07 |
2009-12-10 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Verwendung von Indol-3-carbonsäureestern zur Hemmung der mikrosomalen Prostaglandin E2 Synthase
|
DE102008015432A1
(de)
|
2008-06-12 |
2009-12-17 |
Eberhard-Karls-Universität Tübingen |
Verwendung von Pirinixinsäure-Derivaten zur Hemmung der Prostaglandin E2 Synthese
|
DK2313111T3
(da)
|
2008-08-01 |
2013-12-02 |
Ventirx Pharmaceuticals Inc |
Toll-lignende receptoragonistformuleringer og anvendelse deraf
|
US8652843B2
(en)
|
2008-08-12 |
2014-02-18 |
Oncomed Pharmaceuticals, Inc. |
DDR1-binding agents and methods of use thereof
|
UY32138A
(es)
|
2008-09-25 |
2010-04-30 |
Boehringer Ingelheim Int |
Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
|
US8450321B2
(en)
|
2008-12-08 |
2013-05-28 |
Gilead Connecticut, Inc. |
6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
|
CN102272134B
(zh)
|
2008-12-09 |
2013-10-16 |
吉里德科学公司 |
Toll样受体调节剂
|
CN102257001A
(zh)
|
2008-12-19 |
2011-11-23 |
诺瓦提斯公司 |
治疗自体免疫和炎性病症的可溶性多肽
|
WO2010083253A2
(en)
|
2009-01-14 |
2010-07-22 |
Viral Logic Systems Technology Corp. |
Cd47 related compositions and methods for treating immunological diseases and disorders
|
HUE062339T2
(hu)
|
2009-02-13 |
2023-10-28 |
Immunomedics Inc |
Sejten belül hasítható kötést tartalmazó immunkonjugátumok
|
UY32470A
(es)
|
2009-03-05 |
2010-10-29 |
Boehringer Ingelheim Int |
Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones
|
TWI491606B
(zh)
|
2009-07-13 |
2015-07-11 |
Gilead Sciences Inc |
調節細胞凋亡信號之激酶的抑制劑
|
US8524702B2
(en)
|
2009-08-18 |
2013-09-03 |
Ventirx Pharmaceuticals, Inc. |
Substituted benzoazepines as toll-like receptor modulators
|
BR112012003757A2
(pt)
|
2009-08-18 |
2020-08-11 |
Ventirx Pharmaceuticals, Inc. |
benzoazepinas substituídas como moduladores de receptor tipo dobre de sino
|
US20110071115A1
(en)
*
|
2009-09-11 |
2011-03-24 |
Cylene Pharmaceuticals, Inc. |
Pharmaceutically useful heterocycle-substituted lactams
|
WO2011049825A1
(en)
|
2009-10-22 |
2011-04-28 |
Gilead Sciences, Inc. |
Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections
|
JP5579862B2
(ja)
|
2009-10-23 |
2014-08-27 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
ミクロソームプロスタグランジンe2シンターゼ−1のインヒビター
|
CN102869682B
(zh)
|
2009-11-18 |
2016-10-19 |
曼康公司 |
单克隆抗体及其诊断用途
|
WO2011068845A1
(en)
|
2009-12-02 |
2011-06-09 |
Immunomedics, Inc. |
Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
|
EP2516458A1
(en)
|
2009-12-22 |
2012-10-31 |
Novartis AG |
Tetravalent cd47-antibody constant region fusion protein for use in therapy
|
KR101689421B1
(ko)
|
2009-12-30 |
2016-12-23 |
아르퀼 인코포레이티드 |
치환된 이미다조피리디닐-아미노피리딘 화합물
|
CN103370080A
(zh)
|
2010-02-04 |
2013-10-23 |
吉联亚生物科技有限公司 |
结合赖氨酰氧化酶样2(loxl2)的抗体和其使用方法
|
JP5889875B2
(ja)
|
2010-05-07 |
2016-03-22 |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC |
アザインダゾール
|
LT3789038T
(lt)
|
2010-05-14 |
2022-12-12 |
The Board Of Trustees Of The Leland Stanford Junior University |
Humanizuoti ir chimeriniai monokloniniai antikūnai prieš cd47
|
WO2011146862A1
(en)
|
2010-05-21 |
2011-11-24 |
Bellicum Pharmaceuticals, Inc. |
Methods for inducing selective apoptosis
|
US8586604B2
(en)
|
2010-08-20 |
2013-11-19 |
Boehringer Ingelheim International Gmbh |
Inhibitors of the microsomal prostaglandin E2 synthase-1
|
US8759537B2
(en)
|
2010-08-20 |
2014-06-24 |
Boehringer Ingelheim International Gmbh |
3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents
|
MA34527B1
(fr)
|
2010-08-27 |
2013-09-02 |
Gilead Biologics Inc |
Anticorps contre la metalloproteinase de matrice 9
|
CA2812787A1
(en)
|
2010-10-01 |
2012-04-05 |
Robert Hershberg |
Methods for the treatment of allergic diseases
|
JP5951615B2
(ja)
|
2010-10-01 |
2016-07-13 |
ベンティアールエックス ファーマシューティカルズ, インコーポレイテッドVentiRx Pharmaceuticals,Inc. |
Tlrアゴニストの治療用途および組み合わせ治療
|
WO2012054825A1
(en)
|
2010-10-22 |
2012-04-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-mage-a3 t cell receptors and related materials and methods of use
|
PL3214091T3
(pl)
|
2010-12-09 |
2019-03-29 |
The Trustees Of The University Of Pennsylvania |
Zastosowanie komórek T modyfikowanych chimerycznymi receptorami antygenowymi do leczenia nowotworów
|
US8466186B2
(en)
|
2010-12-10 |
2013-06-18 |
Boehringer Ingelheim International Gmbh |
Compounds
|
UY33779A
(es)
|
2010-12-10 |
2012-07-31 |
Boehringer Ingelheim Int |
?2-(fenilamino)-1H-bencimidazol-5-carboxamidas novedosas?
|
US9096532B2
(en)
|
2010-12-13 |
2015-08-04 |
The Regents Of The University Of California |
Pyrazole inhibitors of COX-2 and sEH
|
AR084174A1
(es)
|
2010-12-21 |
2013-04-24 |
Lilly Co Eli |
Compuestos de imidazol-2-benzamida utiles para el tratamiento de osteoartritis y una composicion farmaceutica
|
MX348935B
(es)
|
2011-01-12 |
2017-07-03 |
Ventirx Pharmaceuticals Inc |
Benzoazepinas sustituidas como moduladores de receptores tipo toll.
|
PL2663550T3
(pl)
|
2011-01-12 |
2017-07-31 |
Ventirx Pharmaceuticals, Inc. |
Podstawione benzoazepiny jako modulatory receptora toll-podobnego
|
ME03782B
(me)
|
2011-04-08 |
2021-04-20 |
Janssen Sciences Ireland Unlimited Co |
Derivati pirimidina za tretman virusnih infekcija
|
AR086044A1
(es)
|
2011-05-12 |
2013-11-13 |
Imclone Llc |
Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos
|
JP6050329B2
(ja)
|
2011-05-18 |
2016-12-21 |
ヤンセン・サイエンシズ・アイルランド・ユーシー |
ウイルス感染およびその他の疾患を治療するためのキナゾリン誘導体
|
AR086254A1
(es)
|
2011-05-26 |
2013-11-27 |
Lilly Co Eli |
Derivados de imidazol utiles para el tratamiento de artritis
|
WO2012170250A1
(en)
|
2011-06-07 |
2012-12-13 |
Radiation Control Technologies, Inc. |
Morpholino oligonucleotides capable of inhibiting cd47-mediated cellular damage and uses thereof
|
WO2013024898A1
(ja)
|
2011-08-18 |
2013-02-21 |
日本新薬株式会社 |
ヘテロ環誘導体及び医薬
|
US9550835B2
(en)
|
2011-08-23 |
2017-01-24 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-DDR1 antibody having anti-tumor activity
|
GB201115529D0
(en)
|
2011-09-08 |
2011-10-26 |
Imp Innovations Ltd |
Antibodies, uses and methods
|
CA2848209C
(en)
|
2011-09-15 |
2021-06-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
T cell receptors recognizing hla-a1- or hla-cw7-restricted mage
|
WO2013041865A1
(en)
|
2011-09-22 |
2013-03-28 |
Immunocore Limited |
T cell receptors
|
EP2763994A4
(en)
|
2011-10-04 |
2015-08-26 |
Gilead Calistoga Llc |
NEW QUINOXALINE INHIBITORS OF THE PI3K PATH
|
WO2013056352A1
(en)
|
2011-10-19 |
2013-04-25 |
University Health Network |
Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers
|
MX2014005728A
(es)
|
2011-11-11 |
2014-05-30 |
Rinat Neuroscience Corp |
Anticuerpos especificos para antigeno de la superficie celular de trofoblasto-2 y sus usos.
|
WO2013072825A1
(en)
|
2011-11-16 |
2013-05-23 |
Glenmark Pharmaceuticals S.A. |
Phtalazinone derivatives as mpegs -1 inhibitors
|
US9427464B2
(en)
|
2011-11-22 |
2016-08-30 |
Chiome Bioscience Inc. |
Anti-human TROP-2 antibody having an antitumor activity in vivo
|
KR20190007106A
(ko)
|
2011-12-21 |
2019-01-21 |
노비라 테라퓨틱스, 인코포레이티드 |
B형 간염의 항바이러스성 제제
|
CN104136037B
(zh)
|
2012-01-17 |
2018-02-23 |
小利兰·斯坦福大学托管委员会 |
高亲和力SIRP‑α试剂
|
UY34573A
(es)
|
2012-01-27 |
2013-06-28 |
Gilead Sciences Inc |
Inhibidor de la quinasa que regula la señal de la apoptosis
|
WO2013116562A1
(en)
|
2012-02-03 |
2013-08-08 |
Gilead Calistoga Llc |
Compositions and methods of treating a disease with (s)-4 amino-6-((1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
|
KR102100388B1
(ko)
|
2012-02-06 |
2020-04-13 |
인히브릭스, 인크. |
Cd47 항체 및 그 사용 방법
|
MY169159A
(en)
|
2012-02-08 |
2019-02-19 |
Janssen R&D Ireland |
Piperidino-pyrimidine derivatives for the treatment of viral infections
|
WO2013153535A1
(en)
|
2012-04-13 |
2013-10-17 |
Glenmark Pharmaceuticals S.A. |
TRICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS
|
TWI568722B
(zh)
|
2012-06-15 |
2017-02-01 |
葛蘭馬克製藥公司 |
作爲mPGES-1抑制劑之三唑酮化合物
|
US9284304B2
(en)
|
2012-08-10 |
2016-03-15 |
Janssen Sciences Ireland Uc |
Substituted pyrimidines as toll-like receptor modulators
|
US9682143B2
(en)
|
2012-08-14 |
2017-06-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
US10227357B2
(en)
|
2012-09-06 |
2019-03-12 |
Plexxikon Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
TW201427995A
(zh)
|
2012-09-24 |
2014-07-16 |
Gilead Sciences Inc |
抗ddr1抗體
|
ES2670513T3
(es)
|
2012-10-10 |
2018-05-30 |
Janssen Sciences Ireland Uc |
Derivados pirrolo[3,2-d]pirimidínicos para el tratamiento de infecciones víricas y otras enfermedades
|
WO2014064215A1
(en)
|
2012-10-24 |
2014-05-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING β-CELL SURVIVAL
|
MX361585B
(es)
|
2012-11-16 |
2018-12-11 |
Janssen Sciences Ireland Uc |
Derivados 2-aminoquinazolínicos sustituidos heterocíclicos para el tratamiento de infecciones víricas.
|
JP6392770B2
(ja)
|
2012-12-03 |
2018-09-19 |
ノビミューン エスアー |
抗cd47抗体およびその使用方法
|
KR20150093770A
(ko)
|
2012-12-12 |
2015-08-18 |
베스쿨럭스 인코포레이티드 |
치료적 cd47 항체
|
US10744129B2
(en)
|
2012-12-13 |
2020-08-18 |
Immunomedics, Inc. |
Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
|
US10413539B2
(en)
|
2012-12-13 |
2019-09-17 |
Immunomedics, Inc. |
Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
|
US9492566B2
(en)
|
2012-12-13 |
2016-11-15 |
Immunomedics, Inc. |
Antibody-drug conjugates and uses thereof
|
JP6207100B2
(ja)
|
2012-12-21 |
2017-10-04 |
ギリアード カリストガ エルエルシー |
イソキノリノンまたはキナゾリノンホスファチジルイノシトール3−キナーゼ阻害剤
|
BR112015014585A2
(pt)
|
2012-12-21 |
2017-07-11 |
Gilead Calistoga Llc |
composto, composição farmacêutica, e, método de tratamento de um ser humano
|
UY35240A
(es)
|
2012-12-21 |
2014-07-31 |
Plexxikon Inc |
Compuestos y métodos para la modulación de quinasas y sus indicaciones
|
AU2014211454B2
(en)
|
2013-01-29 |
2018-04-05 |
Max-Delbruck-Centrum Fur Molekulare Medizin (Mdc) Berlin-Buch |
High avidity binding molecules recognizing MAGE-A1
|
UA118751C2
(uk)
|
2013-02-21 |
2019-03-11 |
ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі |
Похідні 2-амінопіримідину для лікування вірусних інфекцій
|
US8993771B2
(en)
|
2013-03-12 |
2015-03-31 |
Novira Therapeutics, Inc. |
Hepatitis B antiviral agents
|
JP6361039B2
(ja)
|
2013-04-03 |
2018-07-25 |
アイビーシー ファーマスーティカルズ,インコーポレイテッド |
疾患に対する免疫反応を誘導するための併用療法
|
WO2014167444A1
(en)
|
2013-04-08 |
2014-10-16 |
Glenmark Pharmaceuticals S.A. |
SUBSTITUTED BICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS
|
EA028319B1
(ru)
|
2013-06-14 |
2017-11-30 |
Джилид Калистога Ллс |
Ингибиторы фосфатидилинозитол-3-киназы
|
GB201313377D0
(en)
|
2013-07-26 |
2013-09-11 |
Adaptimmune Ltd |
T cell receptors
|
WO2015059618A1
(en)
|
2013-10-22 |
2015-04-30 |
Glenmark Pharmaceuticals S.A. |
SUBSTITUTED PYRIMIDINE COMPOUNDS AS mPGES-1 INHIBITORS
|
US9290505B2
(en)
|
2013-12-23 |
2016-03-22 |
Gilead Sciences, Inc. |
Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
|
RU2705367C2
(ru)
|
2013-12-25 |
2019-11-07 |
Дайити Санкио Компани, Лимитед |
Конъюгат анти-trop2 антитело-лекарственное средство
|
WO2015134536A1
(en)
|
2014-03-04 |
2015-09-11 |
Plexxikon Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
CA2939293C
(en)
|
2014-03-11 |
2023-10-03 |
The Board Of Trustees Of The Leland Standford Junior University |
Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies
|
DK3129023T3
(da)
|
2014-03-27 |
2021-05-25 |
Eicosis Llc |
Potente opløselige epoxidhydrolase-inhibitorer
|
CN106573969B
(zh)
|
2014-04-10 |
2021-07-30 |
西雅图儿童医院(Dba西雅图儿童研究所) |
药物相关的转基因表达
|
HUE052925T2
(hu)
|
2014-04-14 |
2021-05-28 |
Shanghai hengrui pharmaceutical co ltd |
Amid származékok és azok gyógyászatilag elfogadott sói, elõállítási módszere és gyógyászati alkalmazása
|
TWI702228B
(zh)
|
2014-08-08 |
2020-08-21 |
美商Alx腫瘤技術股份有限公司 |
信號調節蛋白α(signal-regulatory protein α, SIRP-α)變體構築物及其用途
|
WO2016022971A1
(en)
|
2014-08-08 |
2016-02-11 |
The Board Of Trustees Of The Leland Stanford Junior University |
Sirp alpha-antibody fusion proteins
|
EP3643727A1
(en)
|
2014-08-15 |
2020-04-29 |
Merck Patent GmbH |
Sirp-alpha immunoglobulin fusion proteins
|
TWI751102B
(zh)
|
2014-08-28 |
2022-01-01 |
美商奇諾治療有限公司 |
對cd19具專一性之抗體及嵌合抗原受體
|
JO3474B1
(ar)
|
2014-08-29 |
2020-07-05 |
Amgen Inc |
مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1
|
MX2017004007A
(es)
|
2014-09-28 |
2018-05-07 |
Univ California |
Modulacion de celulas mieloides estimulantes y no estimulantes.
|
GB201417803D0
(en)
|
2014-10-08 |
2014-11-19 |
Adaptimmune Ltd |
T cell receptors
|
JO3581B1
(ar)
|
2014-10-29 |
2020-07-05 |
Lilly Co Eli |
مركبات ميثيل-بيبيريدين جديدة مفيدة لتثبيط إنزيم سينثاز -1 بروستاجلاندين e2 ميكروسومي
|
TW201627299A
(zh)
|
2014-10-29 |
2016-08-01 |
美國禮來大藥廠 |
用於抑制微粒體前列腺素e合成酶1之新穎羧酸化合物
|
BR112017010303A2
(pt)
|
2014-11-18 |
2018-05-15 |
Janssen Pharmaceutica Nv |
anticorpos anti-cd47, métodos e usos
|
JP2018500930A
(ja)
|
2014-12-04 |
2018-01-18 |
アブルッツォ・セラノスティックス・エッセ・エッレ・エッレ |
ヒト化抗trop−2モノクローナル抗体及びその使用
|
US20160158360A1
(en)
|
2014-12-05 |
2016-06-09 |
Genentech, Inc. |
Methods and compositions for treating cancer using pd-1 axis antagonists and hpk1 antagonists
|
AU2015362748A1
(en)
|
2014-12-15 |
2017-04-27 |
Bellicum Pharmaceuticals, Inc. |
Methods for controlled elimination of therapeutic cells
|
US10870699B2
(en)
|
2014-12-30 |
2020-12-22 |
Celgene Corporation |
Anti-CD47 antibodies and uses thereof
|
AR103868A1
(es)
|
2015-03-04 |
2017-06-07 |
Sorrento Therapeutics Inc |
Anticuerpos anti-cd47 como agentes terapéuticos
|
JP2018510627A
(ja)
|
2015-03-10 |
2018-04-19 |
レイデン ユニバーシティ メディカル センター |
メラノーマ優先発現抗原に対して向けられたt細胞レセプターおよびその使用
|
WO2016149562A2
(en)
|
2015-03-17 |
2016-09-22 |
Omniox, Inc. |
Modulation of tumor immunity by protein-mediated 02 delivery
|
CN106188275A
(zh)
|
2015-05-06 |
2016-12-07 |
广州市香雪制药股份有限公司 |
识别ny-eso-1抗原短肽的t细胞受体
|
WO2016179399A1
(en)
|
2015-05-06 |
2016-11-10 |
The Board Of Trustees Of The Leland Stanford Junior University |
High affinity cd47 analogs
|
AU2016256911B2
(en)
|
2015-05-07 |
2022-03-31 |
Agenus Inc. |
Anti-OX40 antibodies and methods of use thereof
|
WO2016191246A2
(en)
|
2015-05-22 |
2016-12-01 |
Memorial Sloan-Kettering Cancer Center |
T cell receptor-like antibodies specific for a prame peptide
|
CN104804093A
(zh)
|
2015-05-27 |
2015-07-29 |
江苏春申堂药业有限公司 |
一种针对cd47的单域抗体
|
MX2017015239A
(es)
|
2015-05-29 |
2018-02-19 |
Juno Therapeutics Inc |
Composicion y metodos para regular interacciones inhibitorias en celulas geneticamente modificadas.
|
WO2016205042A1
(en)
|
2015-06-16 |
2016-12-22 |
The Board Of Trustees Of The Leland Stanford Junior University |
SIRPα AGONIST ANTIBODY
|
KR20180012850A
(ko)
|
2015-06-24 |
2018-02-06 |
유레카 쎄라퓨틱스, 인코포레이티드 |
Ny-eso-1 펩티드/mhc 복합체를 표적화하는 구축물 및 그의 용도
|
US10195175B2
(en)
|
2015-06-25 |
2019-02-05 |
Immunomedics, Inc. |
Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
|
SG10202105964RA
(en)
|
2015-06-25 |
2021-07-29 |
Univ Health Network |
Hpk1 inhibitors and methods of using same
|
KR20180021723A
(ko)
|
2015-06-29 |
2018-03-05 |
다이이찌 산쿄 가부시키가이샤 |
항체-약물 콘주게이트의 선택적 제조 방법
|
RS62151B1
(sr)
|
2015-08-07 |
2021-08-31 |
Alx Oncology Inc |
Konstrukti koji sadrže sirp-alfa domen ili njegovu varijantu
|
EP3347374A1
(en)
|
2015-09-09 |
2018-07-18 |
Immune Design Corp. |
Ny-eso-1 specific tcrs and methods of use thereof
|
CN108633287A
(zh)
|
2015-09-17 |
2018-10-09 |
诺华股份有限公司 |
功效增强的car t细胞治疗
|
RU2748401C2
(ru)
|
2015-09-18 |
2021-05-25 |
Арч Онколоджи, Инк. |
Терапевтические антитела к CD47
|
NZ741324A
(en)
|
2015-09-21 |
2021-09-24 |
Erasmus Univ Medical Center |
Anti-cd47 antibodies and methods of use
|
CN108883173B
(zh)
|
2015-12-02 |
2022-09-06 |
阿吉纳斯公司 |
抗体和其使用方法
|
AU2016364895A1
(en)
|
2015-12-02 |
2018-06-07 |
Agenus Inc. |
Anti-GITR antibodies and methods of use thereof
|
WO2017096276A1
(en)
|
2015-12-02 |
2017-06-08 |
Agenus Inc. |
Anti-gitr antibodies and methods of use thereof
|
MA43389A
(fr)
|
2015-12-02 |
2021-05-12 |
Agenus Inc |
Anticorps anti-ox40 et leurs procédés d'utilisation
|
US20200079862A1
(en)
|
2015-12-03 |
2020-03-12 |
Agenus Inc. |
Anti-ox40 antibodies and methods of use thereof
|
GB201522592D0
(en)
|
2015-12-22 |
2016-02-03 |
Immunocore Ltd |
T cell receptors
|
ES2796378T3
(es)
|
2016-01-11 |
2020-11-26 |
Forty Seven Inc |
Anticuerpos monoclonales anti-cd47 humanizados, de ratón o químicos
|
US20170224837A1
(en)
|
2016-02-10 |
2017-08-10 |
Immunomedics, Inc. |
Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers
|
US11306107B2
(en)
|
2016-02-25 |
2022-04-19 |
Amgen Inc. |
Compounds that inhibit MCL-1 protein
|
WO2017160861A1
(en)
|
2016-03-15 |
2017-09-21 |
The Regents Of The University Of California |
Inhibitors for soluble epoxide hydrolase (seh) and fatty acid amide hydrolase (faah)
|
CN107286077B
(zh)
|
2016-04-01 |
2021-04-02 |
合肥中科普瑞昇生物医药科技有限公司 |
一种选择性的c-kit激酶抑制剂
|
CA3020530A1
(en)
|
2016-04-08 |
2017-10-12 |
Adaptimmune Limited |
T cell receptors
|
RS63371B1
(sr)
|
2016-04-08 |
2022-08-31 |
Immunocore Ltd |
T ćelijski receptori
|
RU2018138838A
(ru)
|
2016-04-08 |
2020-05-14 |
Адаптимьюн Лимитед |
Т-клеточные рецепторы
|
CA3020555A1
(en)
|
2016-04-08 |
2017-10-12 |
Adaptimmune Limited |
T cell receptors
|
WO2017178653A2
(en)
|
2016-04-14 |
2017-10-19 |
Ose Immunotherapeutics |
NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS
|
WO2017189254A1
(en)
|
2016-04-26 |
2017-11-02 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-kk-lc-1 t cell receptors
|
EP3454900A4
(en)
|
2016-05-09 |
2020-01-29 |
Celgene Corporation |
CD47 ANTIBODIES AND METHOD FOR USE THEREOF
|
EP3243522A1
(en)
|
2016-05-10 |
2017-11-15 |
Université Pierre et Marie Curie (Paris 6) |
Agonist agents of cd47 inducing programmed cell death and their use in the treatments of diseases associated with defects in programmed cell death
|
CA3026784A1
(en)
|
2016-06-07 |
2017-12-14 |
Jacobio Pharmaceuticals Co., Ltd. |
Heterocyclic pyrazine derivatives useful as shp2 inhibitors
|
CN106084052B
(zh)
|
2016-06-17 |
2019-12-27 |
长春金赛药业股份有限公司 |
抗cd47单克隆抗体及其应用
|
ES2800339T3
(es)
|
2016-06-30 |
2020-12-29 |
Gilead Sciences Inc |
4,6-diaminoquinazolinas como moduladores de cuna y métodos de uso de los mismos
|
CA3031034A1
(en)
|
2016-08-03 |
2018-02-08 |
The Board Of Trustees Of The Leland Stanford Junior University |
Disrupting fc receptor engagement on macrophages enhances efficacy of anti-sirpalpha antibody therapy
|
CN106297966A
(zh)
|
2016-08-22 |
2017-01-04 |
广东纳路纳米科技有限公司 |
一种金属纳米线‑抗氧化材料复合的透明导电膜及其制备
|
WO2018049191A1
(en)
|
2016-09-09 |
2018-03-15 |
Incyte Corporation |
Pyrazolopyridone derivatives as hpk1 modulators and uses thereof for the treatment of cancer
|
CN115819417A
(zh)
|
2016-09-09 |
2023-03-21 |
因赛特公司 |
作为hpk1调节剂的吡唑并吡啶衍生物及其用于治疗癌症的用途
|
US20180072741A1
(en)
|
2016-09-09 |
2018-03-15 |
Incyte Corporation |
Pyrazolopyrimidine compounds and uses thereof
|
WO2018049214A1
(en)
|
2016-09-09 |
2018-03-15 |
Incyte Corporation |
Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
|
JOP20190009A1
(ar)
|
2016-09-21 |
2019-01-27 |
Alx Oncology Inc |
أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
|
BR112019008010A2
(pt)
|
2016-10-20 |
2019-07-09 |
I Mab |
anticorpo monoclonal isolado ou fragmento imunologicamente ativo do mesmo, anticorpo monoclonal biespecífico isolado, composição farmacêutica, método para tratamento de uma doença em um sujeito humano em necessidade do mesmo, proteína de fusão, epítopo imunodominante codificado pelo gene cd47, e, molécula biológica
|
WO2018075960A1
(en)
|
2016-10-21 |
2018-04-26 |
Tioma Therapeutics, Inc. |
Therapeutic cd47 antibodies
|
EP3538557A4
(en)
|
2016-11-08 |
2020-11-18 |
Ablexis, LLC |
ANTI-CD47 ANTIBODIES
|
MA46770A
(fr)
|
2016-11-09 |
2019-09-18 |
Agenus Inc |
Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
|
AU2017363257B2
(en)
|
2016-11-22 |
2021-08-19 |
Dana-Farber Cancer Institute, Inc. |
Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use
|
WO2018097951A1
(en)
|
2016-11-22 |
2018-05-31 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-mage-a3/a6 antibodies
|
WO2018095428A1
(zh)
|
2016-11-28 |
2018-05-31 |
江苏恒瑞医药股份有限公司 |
Cd47抗体、其抗原结合片段及其医药用途
|
US11180482B2
(en)
|
2016-11-30 |
2021-11-23 |
Ariad Pharmaceuticals, Inc. |
Anilinopyrimidines as haematopoietic progenitor kinase 1 (HPK1) inhibitors
|
CN110325549B
(zh)
|
2016-12-09 |
2024-03-08 |
艾利妥 |
抗SIRPα抗体及其使用方法
|
CN116178343A
(zh)
|
2016-12-15 |
2023-05-30 |
阿瑞雅德制药公司 |
作为c-kit抑制剂的苯并咪唑化合物
|
CN117105922A
(zh)
|
2016-12-15 |
2023-11-24 |
阿瑞雅德制药公司 |
作为c-kit抑制剂的氨基噻唑化合物
|
CN110741004B
(zh)
|
2016-12-23 |
2023-10-17 |
阿尔维纳斯运营股份有限公司 |
用于迅速加速性纤维肉瘤多肽的靶向降解的化合物和方法
|
CA3049016A1
(en)
|
2017-01-13 |
2018-07-19 |
Agenus Inc. |
T cell receptors that bind to ny-eso-1 and methods of use thereof
|
US11267885B2
(en)
|
2017-01-26 |
2022-03-08 |
Zlip Holding Limited |
CD47 antigen binding unit and uses thereof
|
MX2019009046A
(es)
|
2017-01-31 |
2019-10-30 |
Arvinas Operations Inc |
Ligandos de cereblon y compuestos bifuncionales que comprenden el mismo.
|
CN110402248B
(zh)
|
2017-03-15 |
2023-01-06 |
豪夫迈·罗氏有限公司 |
作为hpk1抑制剂的氮杂吲哚类
|
SG11201908527SA
(en)
|
2017-03-15 |
2019-10-30 |
Hutchinson Fred Cancer Res |
High affinity mage-a1-specific tcrs and uses thereof
|
DE102017106305A1
(de)
|
2017-03-23 |
2018-09-27 |
Immatics Biotechnologies Gmbh |
Neue T-Zellrezeptoren und deren Verwendung in Immuntherapien gegen prame-positive Krebsarten
|
EP3601239A4
(en)
|
2017-03-23 |
2020-05-13 |
Jacobio Pharmaceuticals Co., Ltd. |
INNOVATIVE HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS
|
JP2020512314A
(ja)
|
2017-03-27 |
2020-04-23 |
イミューノメディクス、インコーポレイテッドImmunomedics, Inc. |
サシツズマブゴビテカンとRAD51阻害剤を用いたTrop−2発現トリプルネガティブ乳癌の治療
|
US10407424B2
(en)
|
2017-03-30 |
2019-09-10 |
Genentech, Inc. |
Naphthyridines as inhibitors of HPK1
|
AU2018243770A1
(en)
|
2017-03-30 |
2019-09-19 |
F. Hoffmann-La Roche Ag |
Isoquinolines as inhibitors of HPK1
|
JP6453507B2
(ja)
|
2017-03-30 |
2019-01-16 |
アムジエン・インコーポレーテツド |
Mcl−1タンパク質を阻害する化合物
|
US10851164B2
(en)
|
2017-04-13 |
2020-12-01 |
Aduro Biotech Holdings, Europe B.V. |
Anti-SIRPα antibodies
|
JOP20180040A1
(ar)
|
2017-04-20 |
2019-01-30 |
Gilead Sciences Inc |
مثبطات pd-1/pd-l1
|
TWI710574B
(zh)
|
2017-05-16 |
2020-11-21 |
荷蘭商拜恩迪斯公司 |
抗訊號調節蛋白α(SIRPα)抗體
|
WO2018217227A1
(en)
|
2017-05-24 |
2018-11-29 |
Immunomedics, Inc. |
Novel anti-pd-1 checkpoint inhibitor antibodies that block binding of pd-l1 to pd-1
|
CN110709516B
(zh)
|
2017-06-05 |
2023-06-27 |
国立大学法人三重大学 |
识别来自mage-a4的肽的抗原结合性蛋白
|
WO2018223909A1
(zh)
|
2017-06-05 |
2018-12-13 |
成都海创药业有限公司 |
一种嵌合分子及其制备和应用
|
WO2018226542A1
(en)
|
2017-06-09 |
2018-12-13 |
Arvinas, Inc. |
Modulators of proteolysis and associated methods of use
|
CN109096395B
(zh)
|
2017-06-20 |
2022-06-24 |
华兰生物工程股份有限公司 |
阻断型cd47纳米抗体及其用途
|
WO2018237026A1
(en)
|
2017-06-20 |
2018-12-27 |
C4 Therapeutics, Inc. |
N / O-LINKED DEGRONS AND DEGRONIMERS FOR DEGRADATION OF PROTEINS
|
GB201709866D0
(en)
|
2017-06-20 |
2017-08-02 |
Immunocore Ltd |
T cell receptors
|
PL3658589T3
(pl)
|
2017-07-26 |
2024-03-18 |
Forty Seven, Inc. |
Przeciwciała anty-sirp-alfa i powiązane sposoby
|
NZ761568A
(en)
|
2017-08-02 |
2022-11-25 |
Phanes Therapeutics Inc |
Anti-cd47 antibodies and uses thereof
|
EP3664845A4
(en)
|
2017-08-08 |
2021-03-10 |
Pionyr Immunotherapeutics, Inc. |
COMPOSITIONS AND METHODS OF DEACTIVATION OF MYELOID CELLS EXPRESSING TREM1
|
CN107446050A
(zh)
|
2017-08-11 |
2017-12-08 |
百奥泰生物科技(广州)有限公司 |
Trop2阳性疾病治疗的化合物及方法
|
WO2019034895A1
(en)
|
2017-08-18 |
2019-02-21 |
Ultrahuman Four Limited |
LIAISON AGENTS
|
TWI793151B
(zh)
|
2017-08-23 |
2023-02-21 |
瑞士商諾華公司 |
3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
|
CN109422811A
(zh)
|
2017-08-29 |
2019-03-05 |
信达生物制药(苏州)有限公司 |
抗cd47抗体及其用途
|
CN108503708B
(zh)
|
2017-09-01 |
2021-07-30 |
北京智仁美博生物科技有限公司 |
抗人cd47抗体及其用途
|
CN111278816B
(zh)
|
2017-09-04 |
2024-03-15 |
C4医药公司 |
二氢喹啉酮
|
EP3679027A1
(en)
|
2017-09-04 |
2020-07-15 |
C4 Therapeutics, Inc. |
Dihydrobenzimidazolones
|
CN109422726B
(zh)
|
2017-09-04 |
2022-10-28 |
华东理工大学 |
CD47/SIRPα的阻断剂及其应用
|
US20200239530A1
(en)
|
2017-09-27 |
2020-07-30 |
Vividion Therapeutics, Inc. |
Compounds and methods of modulating protein degradation
|
WO2019079701A1
(en)
|
2017-10-20 |
2019-04-25 |
Dana-Farber Cancer Institute, Inc. |
HETEROBIFUNCTIONAL COMPOUNDS HAVING IMPROVED SPECIFICITY FOR BRD4 BROMODOMAINE
|
WO2019084026A1
(en)
|
2017-10-24 |
2019-05-02 |
Genentech, Inc. |
(4-HYDROXYPYRROLIDIN-2-YL) -HETEROCYCLIC COMPOUNDS AND METHODS OF USE
|
WO2019084030A1
(en)
|
2017-10-24 |
2019-05-02 |
Genentech, Inc. |
(4-HYDROXYPYRROLIDIN-2-YL) -HYDROXAMATE COMPOUNDS AND METHODS OF USE
|
WO2019084538A1
(en)
|
2017-10-27 |
2019-05-02 |
Board Of Regents, The University Of Texas System |
TUMOR SPECIFIC ANTIBODIES, T CELL RECEPTORS AND METHODS OF IDENTIFICATION THEREOF
|
KR20200079511A
(ko)
|
2017-11-01 |
2020-07-03 |
허밍버드 바이오사이언스 홀딩스 피티이. 엘티디. |
Cd47 항원-결합 분자
|
US11065231B2
(en)
|
2017-11-17 |
2021-07-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
|
WO2019103203A1
(ko)
|
2017-11-24 |
2019-05-31 |
주식회사 젬백스앤카엘 |
신규 펩티드 및 이를 포함한 조성물
|
KR20200091901A
(ko)
|
2017-12-01 |
2020-07-31 |
시애틀 지네틱스, 인크. |
암을 치료하기 위한 cd47 항체 및 이의 용도
|
CN109879957B
(zh)
|
2017-12-06 |
2022-03-18 |
香雪生命科学技术(广东)有限公司 |
针对prame的高亲和力t细胞受体
|
AU2018383709A1
(en)
|
2017-12-12 |
2020-07-16 |
Pionyr Immunotherapeutics, Inc. |
Anti-TREM2 antibodies and related methods
|
EA202091267A1
(ru)
|
2018-01-12 |
2020-11-03 |
Ориджен Дискавери Текнолоджис Лимитед |
1,2,4-оксадиазольные соединения в качестве ингибиторов сигнальных путей cd47
|
TW201932493A
(zh)
|
2018-01-24 |
2019-08-16 |
大陸商南京傳奇生物科技有限公司 |
不致顯著紅血球凝集的抗-cd47抗體
|
GB201802201D0
(en)
|
2018-02-09 |
2018-03-28 |
Ultrahuman Five Ltd |
Binding agents
|
MX2020008404A
(es)
|
2018-02-13 |
2020-09-25 |
Gilead Sciences Inc |
Inhibidores de molecula de muerte programada 1 (pd-1)/ligando de molecula de muerte programada 1 (pd-l1).
|
CN110144009B
(zh)
|
2018-02-14 |
2020-01-21 |
上海洛启生物医药技术有限公司 |
Cd47单域抗体及其用途
|
CN111819194A
(zh)
|
2018-02-26 |
2020-10-23 |
基因医疗免疫疗法有限责任公司 |
Nyeso t细胞受体(tcr)
|
TWI702954B
(zh)
|
2018-03-01 |
2020-09-01 |
美商美國禮來大藥廠 |
Cd73抑制劑
|
WO2019173692A2
(en)
|
2018-03-09 |
2019-09-12 |
Agenus Inc. |
Anti-cd73 antibodies and methods of use thereof
|
BR112020017709A2
(pt)
|
2018-03-13 |
2020-12-29 |
Ose Immunotherapeutics |
Anticorpo anti-sirpa humana, fragmento de ligação a antígeno do mesmo ou anticorpo modificado do mesmo, composição farmacêutica, uso de um polipeptídeo, métodos para preparar um anticorpo anti-sirpa humana v1, para aumentar a apresentação cruzada de um antígeno e para avaliar a probabilidade de eficácia de um tratamento, método in vitro ou ex vivo para avaliar a probabilidade de eficácia de um tratamento, e, combinação de compostos
|
WO2019179366A1
(en)
|
2018-03-20 |
2019-09-26 |
Wuxi Biologics (Shanghai) Co. Ltd. |
Novel anti-cd47 antibodies
|
BR112020018927A2
(pt)
|
2018-03-21 |
2021-01-05 |
ALX Oncology Inc. |
Anticorpos contra proteína alfa reguladora de sinal e métodos de uso
|
CN110305212A
(zh)
|
2018-03-27 |
2019-10-08 |
信达生物制药(苏州)有限公司 |
抗cd47抗体及其用途
|
GB201804860D0
(en)
|
2018-03-27 |
2018-05-09 |
Ultrahuman Two Ltd |
CD47 Binding agents
|
CN110386984B
(zh)
|
2018-04-17 |
2022-04-22 |
杭州尚健生物技术有限公司 |
结合cd47蛋白的融合蛋白及其应用
|
JP7469807B2
(ja)
|
2018-04-19 |
2024-04-17 |
ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム |
Mage-b2特異性を有するt細胞受容体およびその使用
|
CN110577597B
(zh)
|
2018-06-11 |
2021-10-22 |
康诺亚生物医药科技(成都)有限公司 |
一种阻断CD47和SIRPα相互作用的抗体
|
US11634490B2
(en)
|
2018-06-15 |
2023-04-25 |
Accurus Biosciences, Inc. |
Blocking antibodies against CD47 and methods of use thereof
|
EP3817769A4
(en)
|
2018-07-05 |
2022-03-30 |
Trican Biotechnology Co., Ltd |
HUMAN ANTI-CD47 ANTIBODIES AND THEIR USES
|
TW202016148A
(zh)
|
2018-07-09 |
2020-05-01 |
大陸商艾比瑪特生物醫藥(上海)有限公司 |
滋養層抗原2(trop2)特異性抗體
|
AU2019302152A1
(en)
|
2018-07-10 |
2021-01-07 |
Daiichi Sankyo Company, Limited |
Anti-sirpalpha antibody
|
FI3820573T3
(fi)
|
2018-07-10 |
2023-11-01 |
Novartis Ag |
3-(5-hydroksi-1-oksoisoindolin-2-yyli)piperidiini-2,6-dionijohdannaisia ja niiden käyttö ikaros-perheen sinkkisormi 2 (ikzf2) -riippuvaisten sairauksien hoidossa
|
AU2019301811B2
(en)
|
2018-07-13 |
2022-05-26 |
Gilead Sciences, Inc. |
PD-1/PD-L1 inhibitors
|
WO2020019135A1
(zh)
|
2018-07-23 |
2020-01-30 |
中国科学院微生物研究所 |
一种抗cd47抗体及其应用
|
EP3836960A4
(en)
|
2018-08-13 |
2022-05-11 |
Arch Oncology, Inc. |
THERAPEUTIC CD47 ANTIBODIES
|
TWI830774B
(zh)
|
2018-08-31 |
2024-02-01 |
大陸商南京聖和藥業股份有限公司 |
抗cd47抗體及其應用
|
WO2020086158A2
(en)
|
2018-09-05 |
2020-04-30 |
The Regents Of The University Of California |
Composition of ny-eso-1-specific t cell receptors restricted on multiple major histocompatibility complex molecules
|
CN110950949B
(zh)
|
2018-09-26 |
2022-04-05 |
香雪生命科学技术(广东)有限公司 |
一种识别ssx2抗原的t细胞受体
|
CN113166245A
(zh)
|
2018-09-27 |
2021-07-23 |
细胞基因公司 |
SIRPα结合蛋白及其使用方法
|
KR20200040407A
(ko)
|
2018-10-10 |
2020-04-20 |
주식회사 노벨티노빌리티 |
신규 항-c-KIT 항체
|
EA202191107A1
(ru)
|
2018-10-23 |
2021-09-17 |
Ридженерон Фармасьютикалз, Инк. |
T-клеточные рецепторы ny-eso-1 и способы их применения
|
CN117105933A
(zh)
|
2018-10-31 |
2023-11-24 |
吉利德科学公司 |
具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物
|
KR102650496B1
(ko)
|
2018-10-31 |
2024-03-26 |
길리애드 사이언시즈, 인코포레이티드 |
Hpk1 억제제로서의 치환된 6-아자벤즈이미다졸 화합물
|
CN113260384A
(zh)
|
2018-11-05 |
2021-08-13 |
西纳福克斯股份有限公司 |
用于靶向表达trop-2的肿瘤的抗体缀合物
|
JP2022510313A
(ja)
|
2018-12-03 |
2022-01-26 |
ダナ-ファーバー キャンサー インスティテュート,インコーポレイテッド |
Heliosの低分子分解誘導剤および使用方法
|
US20220040324A1
(en)
|
2018-12-21 |
2022-02-10 |
Daiichi Sankyo Company, Limited |
Combination of antibody-drug conjugate and kinase inhibitor
|
EP3903817A4
(en)
|
2018-12-27 |
2022-08-17 |
Shionogi & Co., Ltd. |
NEW ANTI-CCR8 ANTIBODY
|
CA3142119A1
(en)
|
2019-05-29 |
2020-12-03 |
Daiichi Sankyo Company, Limited |
Dosage of an antibody-drug conjugate for treating cancer
|
WO2020249063A1
(en)
|
2019-06-13 |
2020-12-17 |
Bio-Thera Solutions, Ltd. |
Methods for the treatment of trop2 positive diseases
|
US20220257632A1
(en)
|
2019-06-20 |
2022-08-18 |
Fred Hutchinson Cancer Research Center |
Microlumenal targeting of cancer cells
|
BR112021026376A2
(pt)
|
2019-06-25 |
2022-05-10 |
Gilead Sciences Inc |
Proteínas de fusão flt3l-fc e métodos de uso
|
US20210093730A1
(en)
|
2019-10-01 |
2021-04-01 |
Immunomedics, Inc. |
Biomarkers for antibody-drug conjugate monotherapy or combination therapy
|
MX2022005839A
(es)
|
2019-11-19 |
2022-06-09 |
Bristol Myers Squibb Co |
Compuestos utiles como inhibidores de la proteina helios.
|
AU2020412875A1
(en)
|
2019-12-24 |
2022-06-23 |
Carna Biosciences, Inc. |
Diacylglycerol kinase modulating compounds
|
AU2021219668A1
(en)
|
2020-02-14 |
2022-08-25 |
Gilead Sciences, Inc. |
Antibodies and fusion proteins that bind to CCR8 and uses thereof
|
CN111534585A
(zh)
|
2020-03-23 |
2020-08-14 |
至本医疗科技(上海)有限公司 |
一种非小细胞肺癌(nsclc)患者免疫疗法预后的方法
|
MX2022013619A
(es)
|
2020-05-01 |
2022-11-16 |
Gilead Sciences Inc |
Compuestos de 2,4-dioxopirimidina que inhiben cd73.
|
TW202216771A
(zh)
|
2020-06-26 |
2022-05-01 |
德商拜耳廠股份有限公司 |
用於治療應用之ccr8抗體
|
WO2022068929A1
(zh)
|
2020-09-30 |
2022-04-07 |
武汉人福创新药物研发中心有限公司 |
嘧啶二酮类化合物及其用途
|
CN112321715B
(zh)
|
2020-11-03 |
2022-05-10 |
博奥信生物技术(南京)有限公司 |
抗trop2纳米抗体及其制备方法和应用
|